$3.18
18.88%
Nasdaq, Mon, Sep 28 2026.
ISIN
US68235C1071
Symbol
OCX

Oncocyte Corporation Stock price

$3.18
-0.95 23.00% 1M
+0.63 24.71% 6M
-4.32 57.60% YTD
-0.05 1.55% 1Y
-0.02 0.63% 3Y
-69.02 95.60% 5Y
-103.22 97.01% 10Y
-158.42 98.03% 20Y
Nasdaq, Closing price Mon, Sep 28 2026
-0.74 18.88%
ISIN
US68235C1071
Symbol
OCX

Is Oncocyte Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$31.0m
Shares outstanding
28.6m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
-35.0%
Return on Equity
496.4%
ROCE
-32.9%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$3.8m | $128.0k
EBITDA
$-15.4m
EBIT
$-16.7m
Net Income
$-58.3m
Free Cash Flow
$-23.5m
Growth (TTM | estimate)
Revenue
178.3% | -93.2%
EBITDA
57.9%
EBIT
55.8%
Net Income
-42.6%
Free Cash Flow
-32.3%
Margin
Gross
52.6%
EBITDA
-400.8%
EBIT
-433.9%
Net
-1,516.1%
Free Cash Flow
-612.5%
More
EPS
$-2.3
FCF per Share
$-0.8
Short interest
2.0%
Employees
48
Rev per Employee
$40.0k

Oncocyte Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Oncocyte Corporation forecast:

5x Buy
63%
3x Hold
38%

Analyst Opinions

8 Analysts have issued a Oncocyte Corporation forecast:

Buy
63%
Hold
38%

Financial data from Oncocyte Corporation

Mar '25
+/-
%
3.84 3.84
178% 178%
100%
- Direct Costs 1.82 1.82
69% 69%
47%
2.02 2.02
552% 552%
53%
- Selling and Administrative Expenses 15 15
14% 14%
385%
- Research and Development Expense 9.36 9.36
16% 16%
244%
-15 -15
58% 58%
-401%
- Depreciation and Amortization 1.27 1.27
11% 11%
33%
EBIT (Operating Income) EBIT -17 -17
56% 56%
-434%
Net Profit -58 -58
43% 43%
-1,517%

In millions USD.

Don't miss a Thing! We will send you all news about Oncocyte Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Head office United States
CEO Mr. Riggs
Employees 48
Founded 2009
Website oncocyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today